(NASDAQ: OCUL) Ocular Therapeutix's forecast annual revenue growth rate of 20.32% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.8%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Ocular Therapeutix's revenue in 2025 is $56,664,000.On average, 5 Wall Street analysts forecast OCUL's revenue for 2025 to be $9,298,304,610, with the lowest OCUL revenue forecast at $8,995,552,926, and the highest OCUL revenue forecast at $10,091,722,818. On average, 5 Wall Street analysts forecast OCUL's revenue for 2026 to be $10,697,574,178, with the lowest OCUL revenue forecast at $9,691,533,810, and the highest OCUL revenue forecast at $12,579,854,478.
In 2027, OCUL is forecast to generate $19,328,259,125 in revenue, with the lowest revenue forecast at $11,013,897,489 and the highest revenue forecast at $27,642,620,760.